NIOX streamlines share schemes with block listing update and cancellations

Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.

NIOX Group has provided an interim update on its active block listings, detailing the remaining unallotted shares across nine current share schemes, which now total just over 8.16 million ordinary shares. The figures reflect recent increases in block listings for several newer schemes, alongside modest allotments during the period from 1 October 2025 to 31 March 2026.

The company is also cancelling block listings linked to five legacy share plans where all options have either been exercised or lapsed, leaving 382,679 unallotted shares that will no longer be issued. This rationalisation of historic schemes simplifies NIOX’s capital management around employee incentives, while clarifying for investors which share plans remain active and capable of further share issuance.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £66.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc, formerly known as Circassia, operates in the healthcare sector and is listed on AIM in London. The company runs a range of employee share schemes, including performance share plans and Save As You Earn schemes in the UK and US, using block listings of ordinary shares to facilitate equity-based remuneration for staff and management.

Average Trading Volume: 802,425

Technical Sentiment Signal: Sell

Current Market Cap: £242.5M

See more data about NIOX stock on TipRanks’ Stock Analysis page.